Daily Sepsis Research Analysis
Three studies advance sepsis science across prevention, risk prediction, and global epidemiology. A multinational prospective cohort showed chlorhexidine-impregnated central lines reduce CLABSI by ~69%. A prospective biomarker study achieved near-early diagnostic performance (AUC ~0.90) for sepsis-associated AKI using TIMP-2×IGFBP-7, Ang-2, and PCT. A global meta-analysis quantified maternal sepsis incidence and risk factors, highlighting stark regional disparities.
Summary
Three studies advance sepsis science across prevention, risk prediction, and global epidemiology. A multinational prospective cohort showed chlorhexidine-impregnated central lines reduce CLABSI by ~69%. A prospective biomarker study achieved near-early diagnostic performance (AUC ~0.90) for sepsis-associated AKI using TIMP-2×IGFBP-7, Ang-2, and PCT. A global meta-analysis quantified maternal sepsis incidence and risk factors, highlighting stark regional disparities.
Research Themes
- Device-related infection prevention in critical care
- Pathophysiology-based biomarkers for early sepsis complications
- Global epidemiology and disparities in maternal sepsis
Selected Articles
1. Global incidence of maternal sepsis: A systematic review and meta-analysis.
Across 44 studies including over 141 million pregnancies, the pooled global incidence of maternal sepsis was 13.16 per 10,000 pregnancies. Incidence varied markedly by region (highest in Africa, lowest in the Americas), and risk factors included age ≥35, multiple gestation, obesity, diabetes, hypertensive disorders including preeclampsia/eclampsia, gestational diabetes, and cesarean delivery.
Impact: Provides contemporary global incidence estimates and risk stratification for maternal sepsis, informing policy and targeted prevention strategies in obstetric care.
Clinical Implications: Supports risk-based screening and prevention (e.g., optimized perioperative prophylaxis for cesarean, hypertensive disorder management, and infection surveillance) and prioritization of resources in high-burden regions.
Key Findings
- Pooled global incidence: 13.16 per 10,000 pregnancies (95% CI 9.91–17.47).
- Regional extremes: Africa 129.17 per 10,000 (95% CI 67.05–248.85) vs. Americas 6.31 per 10,000 (95% CI 4.36–9.12).
- Risk factors: age ≥35, multiple pregnancy, obesity, diabetes (including gestational), hypertensive disorders/preeclampsia–eclampsia, and cesarean delivery.
Methodological Strengths
- PRISMA-compliant systematic search and meta-analysis with JBI critical appraisal.
- Random-effects modeling accounting for heterogeneity across 44 studies and 24 countries.
Limitations
- Substantial regional heterogeneity and uneven study distribution (fewer African studies).
- Variable definitions and ascertainment of maternal sepsis may introduce bias.
Future Directions: Standardize definitions and surveillance, expand high-quality data from underrepresented regions, and evaluate implementation strategies that reduce maternal sepsis burden.
OBJECTIVE: This study investigates the global incidence of maternal sepsis, a life-threatening condition and major cause of maternal mortality. Through a systematic review and meta-analysis, we aim to provide a more precise estimation of its incidence, identify regional variations, and examine associated risk factors to inform improved prevention and management strategies. METHODS: This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search of PubMed/MEDLINE, Scopus, Google Scholar, EMBASE, and the Web of Science was performed for studies published from inception to January 10, 2025. The methodological quality of the included studies was rigorously assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. The pooled incidence rate per 10,000 pregnancies was estimated using a random-effects meta-analysis model to account for study heterogeneity. Furthermore, the analysis also explored the risk factors that contribute to the development of maternal sepsis.
2. Biomarkers of cell cycle arrest, microcirculation dysfunction, and inflammation in the prediction of SA-AKI.
In a prospective cohort of 96 sepsis patients (plus 26 healthy controls), TIMP-2×IGFBP-7, Ang-2, and PCT independently predicted SA-AKI within 72 hours. The combined model achieved high discrimination (AUC 0.898; internal validation AUC 0.899) and was presented as a nomogram with strong calibration.
Impact: Offers a pathophysiology-informed, clinically actionable biomarker panel with near-early diagnostic performance to triage SA-AKI risk.
Clinical Implications: Implement combined TIMP-2×IGFBP-7, Ang-2, and PCT testing during the first 72 hours of sepsis to identify high-risk patients and trigger kidney-protective strategies (hemodynamic optimization, nephrotoxin avoidance, dose adjustment).
Key Findings
- SA-AKI incidence among sepsis patients was 52.08% (50/96) within 72 hours.
- Independent predictors: TIMP-2×IGFBP-7 (OR 2.71), Ang-2 (OR 1.19), and PCT (OR 1.05).
- Predictive model performance: AUC 0.898 with internal validation AUC 0.899; strong discrimination and calibration.
Methodological Strengths
- Prospective observational design with prespecified 72-hour outcome window.
- Pathophysiology-based biomarker selection and internal validation with nomogram.
Limitations
- Single-center study with modest sample size; external validation is lacking.
- Potential spectrum bias and limited assessment of clinical utility and cost-effectiveness.
Future Directions: Conduct multicenter external validation, assess real-time implementation pathways, and evaluate clinical impact on kidney outcomes and resource use.
Sepsis-associated acute kidney injury (SA-AKI) is a severe complication in critically ill patients, with a complex pathogenesis involving in cell cycle arrest, microcirculatory dysfunction, and inflammation. Current diagnostic strategies remain suboptimal. Therefore, this study aimed to evaluate pathophysiology-based biomarkers and develop an improved predictive model for SA-AKI. The prospective observational study was conducted, enrolling 26 healthy individuals and 96 sepsis patients from Peking University Third Hospital. Clinical and laboratory data were collected, and patients were monitored for AKI development within 72 h. Further, sepsis patients were categorized into SA-noAKI (n = 46) and SA-AKI (n = 50) groups. Novel biomarkers, including tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor-binding protein-7 (IGFBP-7), and angiopoietin-2 (Ang-2), were measured in all participants. Among these sepsis patients, the SA-AKI incidence was 52.08% (50/96). Compared to SA-noAKI, the SA-AKI group had significantly higher levels of TIMP-2 (93.55 [79.36, 119.56] ng/mL), IGFBP-7 (27.8 [21.44, 37.29] ng/mL), TIMP-2×IGFBP-7 (2.91 [1.90, 3.55] (ng/mL)²/1000), and Ang-2 (10.61 [5.79, 14.57] ng/mL) (P < 0.05). Accordingly, logistic regression identified TIMP-2×IGFBP-7 (OR = 2.71), Ang-2 (OR = 1.19), and PCT (OR = 1.05) as independent risk factors. The ROC curve of the predictive model demonstrated superior early-stage accuracy (AUC = 0.898), which remained stable during internal validation (AUC = 0.899). Meanwhile, the nomogram exhibited that this model was characterized with excellent discrimination, calibration, and clinical performance.
3. Multicenter, multinational, prospective cohort study of the impact of chlorhexidine impregnated versus plain central lines on central line-associated bloodstream infections.
In a prospective cohort across six countries and eight hospitals (n=6,672), chlorhexidine-impregnated central lines reduced CLABSI from 4.78 to 1.48 per 1,000 line-days (RR 0.31). Subgroup analysis of non-hemodialysis CVCs showed similar benefit (RR 0.29), supporting adoption in varied settings.
Impact: Demonstrates substantial CLABSI reduction with an implementable device-level intervention across diverse international settings.
Clinical Implications: Hospitals—especially in high-CLABSI settings—should consider routine use of chlorhexidine-impregnated central lines within infection-prevention bundles and adapt procurement policies accordingly.
Key Findings
- CLABSI decreased from 4.78 to 1.48 per 1,000 line-days with chlorhexidine-impregnated lines (RR 0.31; 95% CI 0.14–0.67; P=.003).
- In non-hemodialysis CVCs, CLABSI fell from 5.84 to 1.72 per 1,000 line-days (RR 0.29; 95% CI 0.12–0.68; P=.004).
- Multinational, multicenter prospective surveillance across 6 countries and 8 hospitals included 6,672 patients.
Methodological Strengths
- Prospective, multinational multicenter cohort with standardized surveillance (INICC).
- Effect estimates reported with confidence intervals and subgroup analyses.
Limitations
- Non-randomized design susceptible to confounding by indication and bundle adherence differences.
- Imbalance in line-days between groups and potential unmeasured practice variations.
Future Directions: Cluster-RCTs or stepped-wedge trials to confirm causality, and cost-effectiveness analyses to guide procurement in diverse resource settings.
BACKGROUND: We compared the efficacy of chlorhexidine-impregnated central lines (CLs) with plain CLs in preventing central line-associated bloodstream infections (CLABSIs) in critically ill patients. METHODS: The study was conducted from April 2023 to August 2024 in 8 hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. Data were collected prospectively using the INICC Surveillance Online System. Cases and controls were recruited simultaneously. Data were analyzed using t tests, χ² tests, and Fisher exact tests when indicated. Relative risks (RR) and their corresponding 95% confidence intervals (CI) were calculated. RESULTS: A total of 6,672 patients were included. Patients with impregnated CLs had 4,721 CL-days, while those with plain CLs had 18,822 CL-days. The CLABSI rate in patients with impregnated CLs was 1.48 per 1,000 CL-days, compared to 4.78 per 1,000 CL-days in those with plain CLs (RR=0.31, 95%CI=0.14-0.67, P=.003). A subgroup analysis excluding patients with hemodialysis but using central venous catheters (CVCs) showed 1.72 CLABSIs per 1,000 CL-days in patients with impregnated CVCs compared to 5.84 per 1,000 CL-days in those with plain CVCs (RR=0.29, 95%CI=0.12-0.68, P=.004). CONCLUSIONS: This study highlights the significant benefits of impregnated CLs over plain CLs in reducing CLABSI rates, achieving a 69% decrease in incidence.